Celprogen Launches Cancer Stem Cells
Posted on: Wednesday, 23 January 2008, 15:00 CST
Celprogen Inc., a leader in the Stem Cell Research and Therapeutics industry for the development of stem cell technologies for regenerative medicine, today announced that they have successfully isolated and propagated 11 major cancer stem cells. These Cancer Stems were launched in May 2007 at the AACR meeting in Los Angeles and also in December 2007 at ASCB in Washington DC.
Celprogen's cancer stem cells are available for basic science research and drug discovery. The cancer stem cells are as follows: Brain, Breast, Colon, Kidney, Leukemia, Liver, Lungs, Melanoma, Ovarian, and Pancreatic & Prostate.
Celprogen provides the Cancer Stem Cell Tissue culture system which includes cells, pre-coated flasks with extracellular matrix and Medium for growth and proliferation of these cells.
About Celprogen Inc.
Celprogen Inc. is a global Stem Cell Research & Therapeutics company which is developing a proprietary portfolio of unique cancer therapeutics products and life science research tools that includes stem cell technologies for regenerative medicine, as well as bio-engineering products for tissue & organ transplants. Headquartered in San Pedro, California, Celprogen is committed to the research, development, and manufacture of quality Stem Cell products to serve our global community. Additional information about Celprogen is available at http://www.celprogen.com.
Source: Business Wire
Related Articles
- Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
- North American Scientific Completes Sale of Non-Therapeutic Product Line
- North American Scientific to Divest Non-Therapeutic Product Line
- North American Scientific Signs Definitive Agreement to Divest Non-Therapeutic Product Line
- South Texas Accelerated Research Therapeutics Gains Highly Respected Cancer Drug Researcher Michael Wick, Ph.D.
- Renowned Cancer Drug Researcher Chris Takimoto, M.D., Ph.D., Joins South Texas Accelerated Research Therapeutics
- Innovative Pulmonary and PEGylation-Based Therapeutic Product Development Drives Business Strategy of Nektar Therapeutics
- Geron Announces Publication of Study Results Supporting Safety and Utility of Human Embryonic Stem Cell-Derived Therapeutic Product for Treatment of Spinal Cord Injury
- Geron Presents New Data That Document Progress in Development of Therapeutic Products From Human Embryonic Stem Cells
- ProlX Pharmaceuticals Designated Corporate Partner in $5.6 Million Grant to Fund Targeted Therapy Cancer Drug Discovery Research
 |
 |
User Comments (0)
RSS Feeds